Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4420
Source ID: NCT01520818
Associated Drug: Biphasic Insulin Aspart 50
Title: Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2
Interventions: DRUG: biphasic insulin aspart 50|DRUG: biphasic insulin aspart 70|DRUG: biphasic human insulin 30
Outcome Measures: Primary: HbA1c (glycosylated haemoglobin A1c) | Secondary: Blood glucose profiles|Adverse events|Hypoglycaemic episodes|Quality of Life (QoL) assessed via World Health Organization Diabetes Treatment Satisfaction Questionnaire (WHO DTSQ)|Quality of Life (QoL) assessed via Diabetes Health Profile (DHP-2)
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 666
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2000-03
Completion Date: 2001-04
Results First Posted:
Last Update Posted: 2017-01-04
Locations: Novo Nordisk Investigational Site, Aalst, 9300, Belgium|Novo Nordisk Investigational Site, Brussels, 1020, Belgium|Novo Nordisk Investigational Site, Brussels, 1090, Belgium|Novo Nordisk Investigational Site, Edegem, 2650, Belgium|Novo Nordisk Investigational Site, Genk, 3600, Belgium|Novo Nordisk Investigational Site, Jumet, 6040, Belgium|Novo Nordisk Investigational Site, Liège, 4000, Belgium|Novo Nordisk Investigational Site, Amiens, France|Novo Nordisk Investigational Site, Avignon, 84902, France|Novo Nordisk Investigational Site, Bagnols-sur-ceze, 30200, France|Novo Nordisk Investigational Site, Bordeaux, 33076, France|Novo Nordisk Investigational Site, Caen, 14033, France|Novo Nordisk Investigational Site, Colmar, 68024, France|Novo Nordisk Investigational Site, DIJON cedex, 21079, France|Novo Nordisk Investigational Site, Dommartin Les Toul, 54201, France|Novo Nordisk Investigational Site, GRENOBLE cedex, 38043, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, 17019, France|Novo Nordisk Investigational Site, Le Creusot, 71200, France|Novo Nordisk Investigational Site, Lorient, 56322, France|Novo Nordisk Investigational Site, Lyon, 69437, France|Novo Nordisk Investigational Site, Macon, 71000, France|Novo Nordisk Investigational Site, Marseille, 13009, France|Novo Nordisk Investigational Site, Nanterre, 92014, France|Novo Nordisk Investigational Site, Narbonne, 11108, France|Novo Nordisk Investigational Site, NEVERS cedex, 58033, France|Novo Nordisk Investigational Site, Nimes, 30006, France|Novo Nordisk Investigational Site, Orleans, France|Novo Nordisk Investigational Site, Paris, 75007, France|Novo Nordisk Investigational Site, Paris, 75014, France|Novo Nordisk Investigational Site, Reims, 51056, France|Novo Nordisk Investigational Site, Roubaix, 59056, France|Novo Nordisk Investigational Site, Saint Etienne, France|Novo Nordisk Investigational Site, Strasbourg, 67091, France|Novo Nordisk Investigational Site, TOULOUSE cedex, 31054, France|Novo Nordisk Investigational Site, Dublin, DUBLIN 15, Ireland|Novo Nordisk Investigational Site, Dublin, DUBLIN 7, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Alkmaar, 1815 JD, Netherlands|Novo Nordisk Investigational Site, Amersfoort, 3816 CP, Netherlands|Novo Nordisk Investigational Site, Arnhem, Netherlands|Novo Nordisk Investigational Site, Beverwijk, Netherlands|Novo Nordisk Investigational Site, Delft, 2625 AD, Netherlands|Novo Nordisk Investigational Site, Den Bosch, 5223 GV, Netherlands|Novo Nordisk Investigational Site, Den Haag, 2597 AX, Netherlands|Novo Nordisk Investigational Site, Einhoven, Netherlands|Novo Nordisk Investigational Site, Hengelo, 7555 DL, Netherlands|Novo Nordisk Investigational Site, Rotterdam, 3011 TD, Netherlands|Novo Nordisk Investigational Site, Rotterdam, 3021 HC, Netherlands|Novo Nordisk Investigational Site, Ayrsh, KA2 0BE, United Kingdom|Novo Nordisk Investigational Site, Ayr, KA6 6DX, United Kingdom|Novo Nordisk Investigational Site, Bath, BA1 3NG, United Kingdom|Novo Nordisk Investigational Site, Birmingham, B9 5SS, United Kingdom|Novo Nordisk Investigational Site, Brighton, BN2 5BE, United Kingdom|Novo Nordisk Investigational Site, Coventry, CV1 4FH, United Kingdom|Novo Nordisk Investigational Site, Dundee, DD1 9SY, United Kingdom|Novo Nordisk Investigational Site, Edgware, HA8 0AD, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, EH4 2XU, United Kingdom|Novo Nordisk Investigational Site, Exeter, EX2 5AX, United Kingdom|Novo Nordisk Investigational Site, Glasgow, G51 4TF, United Kingdom|Novo Nordisk Investigational Site, Haywards Heath, RH16 4EX, United Kingdom|Novo Nordisk Investigational Site, Ipswich, IP4 5PD, United Kingdom|Novo Nordisk Investigational Site, Leeds, LS9 7TF, United Kingdom|Novo Nordisk Investigational Site, Leicester, LE1 5WW, United Kingdom|Novo Nordisk Investigational Site, London, E11 1NR, United Kingdom|Novo Nordisk Investigational Site, London, N19 3UA, United Kingdom|Novo Nordisk Investigational Site, Manchester, M13 0JE, United Kingdom|Novo Nordisk Investigational Site, Manchester, M8 5RB, United Kingdom|Novo Nordisk Investigational Site, Nottingham, NG7 2UH, United Kingdom|Novo Nordisk Investigational Site, Paisley, PA2 9PL, United Kingdom|Novo Nordisk Investigational Site, Poole, BH15 2JB, United Kingdom|Novo Nordisk Investigational Site, Rugby, CV22 5PX, United Kingdom|Novo Nordisk Investigational Site, Scunthorpe, DN15 7BH, United Kingdom|Novo Nordisk Investigational Site, Southampton, SO14 OYG, United Kingdom|Novo Nordisk Investigational Site, Sunderland, SR4 7TP, United Kingdom|Novo Nordisk Investigational Site, Swansea, SA6 6NL, United Kingdom|Novo Nordisk Investigational Site, Watford, WD18 0HB, United Kingdom|Novo Nordisk Investigational Site, Whiston, L35 5DR, United Kingdom
URL: https://clinicaltrials.gov/show/NCT01520818

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress